Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer.
Br J Cancer
; 105(11): 1693-6, 2011 Nov 22.
Article
en En
| MEDLINE
| ID: mdl-22033274
ABSTRACT
BACKGROUND:
A blood pressure drop after bevacizumab administration and its clinical significance have not been previously reported.METHODS:
Blood pressure data at 0, 90, and 180 min after a total of 162 bevacizumab administrations in 81 advanced colorectal cancer patients were retrospectively investigated.RESULTS:
Twenty-five patients (30%) demonstrated an average temporary drop of 20 mm Hg or more in systolic blood pressure. We classified these 25 patients as group A and the others as group B. Median time-to-treatment failure (TTF) was significantly longer in group A than in group B (291 vs 162 days; P=0.02). Furthermore, the proportion of patients who required intervention with antihypertensive drugs during bevacizumab treatment was significantly higher in group A than in group B (36% vs 4%; P<0.01).CONCLUSION:
This study suggests that a temporary blood pressure drop after bevacizumab administration could be a predictive marker for bevacizumab treatment.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Presión Sanguínea
/
Neoplasias Colorrectales
/
Anticuerpos Monoclonales Humanizados
/
Hipotensión
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Br J Cancer
Año:
2011
Tipo del documento:
Article
País de afiliación:
Japón